AI assistant
Vitrolife — Director's Dealing 2010
Dec 29, 2010
2989_rns_2010-12-29_be838551-d7b1-4ca9-9505-e8e16926a2b7.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Pressmeddelande 29 december 2010 Göteborg
The CEO of Vitrolife acquires additional call options
Magnus Nilsson, the CEO of Vitrolife, acquires additional 50 000 call options in Vitrolife. Magnus hold after the acquisition, 231 000 shares, 150 000 call options and 40 000 warrants.
December 29, 2010 Gothenburg
Magnus Nilsson CEO
Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 61 Anne-Lie Sveder, CFO, phone +46 31 721 80 13
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
______________________________________________________________________________________________________________________
Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
______________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [email protected]. Website: www.vitrolife.com